Is Wave Life Sciences Ltd. (WVE) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.7% / 30% | 24.4% / 30% | 0.1% / 30% | 25.76% / 5% | ✗ NOT HALAL |
| DJIM | 0.7% / 33% | 24.4% / 33% | 0.1% / 33% | 25.76% / 5% | ✗ NOT HALAL |
| MSCI | 2.8% / 33% | 94.3% / 33% | 0.2% / 33% | 25.76% / 5% | ✗ NOT HALAL |
| S&P | 0.7% / 33% | 24.4% / 33% | 0.1% / 33% | 25.76% / 5% | ✗ NOT HALAL |
| FTSE | 2.8% / 33% | 94.3% / 33% | 0.2% / 50% | 25.76% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -327.4% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -55.0% | |
| Return on Assets (ROA) | -27.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$187M |
| Free Cash Flow | -$188M |
| Total Debt | $18M |
| Debt-to-Equity | 3.4 |
| Current Ratio | 6.5 |
| Total Assets | $638M |
Price & Trading
| Last Close | $6.20 |
| 50-Day MA | $12.96 |
| 200-Day MA | $10.19 |
| Avg Volume | 3.2M |
| Beta | -1.7 |
|
52-Week Range
$5.02
| |
About Wave Life Sciences Ltd. (WVE)
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Wave Life Sciences Ltd. (WVE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Wave Life Sciences Ltd. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Wave Life Sciences Ltd.'s debt ratio?
Wave Life Sciences Ltd.'s debt ratio is 0.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.8%.
What are Wave Life Sciences Ltd.'s key financial metrics?
Wave Life Sciences Ltd. has a market capitalization of $1.2B, and revenue of $43M. Return on equity stands at -55.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.